Antleron

Ambachtenlaan 1
3001 Leuven
BE
Antleron
Foundation date
21/11/2014
Sector
#Biotechnology / R&D ServicesTherapeutic areas
- #Cardiovascular
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Injury - poisoning and certain other consequences of external causes
- #Musculoskeletal system and connective tissue
- #Skin and subcutaneous tissue
- #Symptoms - signs and abnormal clinical and laboratory findings - not elsewhere classified
We are Antleron, a nimble team that will revolutionise medicine by leading the development of next generation advanced therapies and medical devices. By merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors we will accelerate the engineering of medicinal products, devices and processes that will change health care and result in a better life for all. The Antleron business philosophy is to create sustainable ventures through risk & reward sharing partnerships.
Upcoming events
All events-
1212 '23
BioFIT 2023
Event by: Eurasanté -
0602 '24
Discovery to Innovation in Animal Health - 2024
Event by: Ghent University, Provaxs, Paul Dick & Associates -
3011 '23
The GxP Academy: Aseptische Training en werken in LAF/Biosafety Cabinet
Event by: Advipro
Latest news
More news-
argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia
20 hours ago
Read more
-
Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
Wednesday November 22nd 2023
Read more
-
argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis
Thursday November 16th 2023
Read more
Jobs
More jobs-
-
-
27/11/23
Antwerp, Brussels, East Flanders, Hainaut, Liège, Limburg, Luxembourg, Namur, Flemish Brabant, Walloon Brabant, West Flanders, Remote
Project Manager Life Science & IVD
Permanent
Thema Group Belgium
More info?
Ellen Telleir
Communication Coordinator